SciELO - Scientific Electronic Library Online

 
vol.36 issue3Determinación de levodropropizina en gotas orales por cromatografía líquida de alta resoluciónUtilización de antiepilépticos en un hospital general de Ciudad de La Habana author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Farmacia

On-line version ISSN 1561-2988

Abstract

GARCIA FARINAS, Anaí; FARINAS REINOSO, Ana Teresa  and  GALVEZ, Ana María. Uso del meprobamato en el tratamiento de la hipertensión arterial: Consecuencias económicas. Rev Cubana Farm [online]. 2002, vol.36, n.3, pp. 157-161. ISSN 1561-2988.

The hypertensive population taking meprobamate as part of the arterial hypertension treatment was characterized and the economic effect of this inadequate therapy for the individual and for the society was calculated. 27 patients over 15 that were treated with this drug were studied. 40.7 % of these patients referred to unappropriated therapeutic properties of this drug as hypotensive. The impossibility to have the drug influenced on the quality of life of the patients. 51.8 % felt uncontrolled when they could not take the drug. Every patient spent between $1.60 and $40.00 a month, depending on the way of acquisition. As a result of the research, it was concluded that the inadequate administration of meprobamate as a hypotensive agent brings about an unnecessary drug dependance that together with the increase of the production demand in the industrial setting, provoke the utilization of resources in its production and affect other options.

Keywords : MEPROBAMATE [therapeutic use]; HYPERTENSION [drug therapy]; COST OF ILLNESS; EXPENDITURES; DRUGS USE HABITS.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License